Brokerages Set Regulus Therapeutics Inc. (NASDAQ:RGLS) Target Price at $10.80

Regulus Therapeutics Inc. (NASDAQ:RGLS) has been assigned a consensus rating of “Moderate Buy” from the six brokerages that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $10.80.

Separately, HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Regulus Therapeutics in a research note on Monday, November 11th.

Regulus Therapeutics Stock Down 3.1 %

Shares of Regulus Therapeutics stock opened at $1.24 on Friday. The firm’s 50 day moving average price is $1.52 and its 200-day moving average price is $1.58. Regulus Therapeutics has a 52-week low of $1.13 and a 52-week high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.03). On average, equities research analysts forecast that Regulus Therapeutics will post -0.88 EPS for the current fiscal year.

Insider Activity at Regulus Therapeutics

In other news, CEO Joseph P. Hagan sold 115,290 shares of the stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $1.26, for a total transaction of $145,265.40. Following the sale, the chief executive officer now owns 222,572 shares of the company’s stock, valued at approximately $280,440.72. This represents a 34.12 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Christopher Ray Aker sold 38,547 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $1.26, for a total transaction of $48,569.22. Following the completion of the sale, the vice president now directly owns 54,634 shares in the company, valued at approximately $68,838.84. This trade represents a 41.37 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 223,998 shares of company stock worth $282,237 in the last three months. Company insiders own 4.35% of the company’s stock.

Institutional Investors Weigh In On Regulus Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Creative Planning purchased a new stake in Regulus Therapeutics in the 3rd quarter valued at about $26,000. SG Americas Securities LLC bought a new position in Regulus Therapeutics during the third quarter worth $33,000. Jane Street Group LLC acquired a new stake in Regulus Therapeutics in the third quarter worth $46,000. Rhumbline Advisers acquired a new stake in Regulus Therapeutics in the second quarter worth $136,000. Finally, JPMorgan Chase & Co. increased its holdings in shares of Regulus Therapeutics by 193.4% during the third quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company’s stock valued at $124,000 after purchasing an additional 52,059 shares during the period. Institutional investors and hedge funds own 92.38% of the company’s stock.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.